Sana Biotechnology, Inc. (SANA)
| Market Cap | 971.25M +149.5% |
| Revenue (ttm) | n/a |
| Net Income | -244.17M |
| EPS | -0.96 |
| Shares Out | 277.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,137,178 |
| Open | 3.620 |
| Previous Close | 3.640 |
| Day's Range | 3.440 - 3.621 |
| 52-Week Range | 1.600 - 6.550 |
| Beta | 2.18 |
| Analysts | Strong Buy |
| Price Target | 7.80 (+122.86%) |
| Earnings Date | May 19, 2026 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therap... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SANA stock is "Strong Buy." The 12-month stock price target is $7.8, which is an increase of 122.86% from the latest price.
News
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas...
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract ...
Sana Biotechnology price target raised to $7 from $6 at Wedbush
Wedbush analyst Martin Fan raised the firm’s price target on Sana Biotechnology (SANA) to $7 from $6 and keeps an Outperform rating on the shares. The firm notes Sana announced
Sana Biotechnology announces SC451 strategic collaboration with Mayo Clinic
Sana Biotechnology (SANA) and Mayo Clinic announced a strategic collaboration to advance development of SC451, Sana’s investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabe...
Sana announces follow-up results from first-in-human study transplanting UP421
Sana Biotechnology (SANA) announced 14-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s...
Sana Biotechnology Transcript: The Citizens Life Sciences Conference 2026
The conference highlighted advances in hypoimmune cell therapies for Type 1 diabetes, including a year-long successful human case and scalable manufacturing progress. In vivo CAR T cell programs are set for clinical trials this year, with human data expected by year-end.
Sana Biotechnology files automatic mixed securities shelf
17:22 EST Sana Biotechnology (SANA) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’...
Sana Biotechnology reports Q4 EPS (16c), consensus (13c)
Cash, cash equivalents, and marketable securities as of December 31, 2025 were $138.4M compared to $152.5M as of December 31, 2024. The decrease of $14.1M was primarily driven by cash
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evad...
Sana Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
Key programs target immune-evasive cell therapies for type 1 diabetes and in vivo CAR T-cells for blood cancers, with pivotal clinical and regulatory milestones expected within 12–24 months. Manufacturing scalability, safety, and commercial strategy are central to future success.
Sana Biotechnology to Present at March 2026 Investor Conferences
SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology appoints Piper as EVP, CFO
Sana Biotechnology (SANA) announced the appointment of Brian Piper as Executive Vice President, EVP, Chief Financial Officer, CFO. Piper was most recently CFO of Scorpion Therapeutics and its post-acq...
Sana Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant progress was reported in developing gene-edited cell therapies for type 1 diabetes and in vivo CAR T platforms, with first-in-human data showing immune evasion and ongoing function. IND filing and phase I trials are planned for this year, and manufacturing scale-up and partnerships are key future priorities.
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology price target raised to $7 from $6 at BofA
BofA raised the firm’s price target on Sana Biotechnology (SANA) to $7 from $6 and keeps a Buy rating on the shares. The firm is updating its price targets for
Sana Biotechnology announces publication of in vivo gene editing
Sana Biotechnology (SANA) announced that Nature Biotechnology has published a journal article titled “In vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered vi...
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology
Sana Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference
The discussion highlighted progress toward a functional cure for type 1 diabetes using gene-modified, immune-evasive islets, with IND submission targeted for next year and clinical trials expected in 2026. Manufacturing scale-up and regulatory alignment are underway, and the in vivo CAR-T platform shows promising preclinical results.
Sana Biotechnology Transcript: Citi Annual Global Healthcare Conference 2025
The company is advancing two main programs: a gene-edited, immune-evasive cell therapy for type 1 diabetes targeting IND and phase I trial next year, and an in vivo CAR T platform for blood cancers and autoimmune diseases. Manufacturing scale and safety are key challenges, with partnerships considered for long-term commercialization and platform diversification.
Sana Biotechnology to Present at December 2025 Investor Conferences
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology Transcript: TD Cowen Immunology and Inflammation Summit
SC451, a gene-modified islet therapy for type 1 diabetes, is advancing toward IND and clinical trials in 2026, with strong proof of concept and a focus on scalable manufacturing. The in vivo CAR T platform is also progressing, with capital allocation ensuring diabetes remains the top priority.
Sana Biotechnology reports Q3 EPS (16c), consensus (19c)
“Given our recent progress and the potentially transformative impact with SC451 in type 1 diabetes, as well as with our in vivo CAR T platform across a range of diseases,
Sana Biotechnology options imply 17.5% move in share price post-earnings
Pre-earnings options volume in Sana Biotechnology (SANA) is normal with calls leading puts 27:1. Implied volatility suggests the market is anticipating a move near 17.5%, or 73c, after results are
Sana Biotechnology price target raised to $8 from $5 at Citizens JMP
Citizens JMP raised the firm’s price target on Sana Biotechnology (SANA) to $8 from $5 and keeps an Outperform rating on the shares. Sana’s enhanced Fusogen platform now offers improved
Sana Biotechnology strength attributed to EMJ Capital long call
Shares of Sana Biotechnology (SANA) are up $1.28, or 29% to $5.73 in afternoon trading after EMJ Capital’s Eric Jackson revealed in a post to X earlier that he is